Skip to content
Triangle logo TriangleGet started
← Study library

NCT00742560 · REGISTRY CONDITION SEARCH

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2018-01-10

The purpose of this study is to evaluate the combination of elotuzumab, lenalidomide, and dexamethasone in subjects with relapsed multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Lenalidomide and Dexamethasone (Phase 1)

→

outcome · POSTED

Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 2)

→

outcome · POSTED

Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 1)

→

outcome · POSTED

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Number of Participants With Infusion Reactions

→

outcome · POSTED

Mean Serum Concentrations of Elotuzumab During Cycle 1

→

outcome · POSTED

Maximum Serum Concentration (Cmax) of Elotuzumab

→

outcome · POSTED

Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of Elotuzumab

→

outcome · POSTED

Systemic Clearance (CL) of Elotuzumab

→

outcome · POSTED

Volume of Distribution (V) of Elotuzumab

→

outcome · POSTED

Serum Half-life (t1/2) of Elotuzumab

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Time to Progression (TTP)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Percentage of Participants With Treatment-emergent Anti-elotuzumab Antibody (ADA)

→

outcome · POSTED

Plasma Cell Myeloma Cytogenetic Subtype

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older with a confirmed diagnosis of multiple myeloma (MM) and documentation of one to three prior therapies. 2. Confirmed evidence of disease progression from immediately prior MM therapy or refractory to the immediately prior treatment. 3. Measurable monoclonal (M-) protein component in serum (≥ 0.5 g/dL) and/or urine (if present), (≥ 0.2 g excreted in a 24 hour collection sample). Subjects with free light chain only disease are excluded. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 5. Creatinine clearance ≥ 50 mL/min measured by Cockcroft-Gault method. 6. Hematologic parameters defined by: * Absolute neutrophil count \>1000 cells/mm\^3 without growth factors for 7 days. * Platelets ≥ 75,000 cells/mm\^3 (75 × 10\^9/L), without platelet transfusion, within 72 hours of screening evaluation. * Hemoglobin ≥ 8 g/dL without red blood cell transfusion within 72 hours of screening. 7. Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) \< 3 × upper limit of normal. 8. Total bilirubin \< 2 × upper limit of normal, direct bilirubin \< 2.0 mg/dL. 9. Negative urine pregnancy test in women of childbearing potential at screening and prior to prescribing lenalidomide. Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin acceptable methods of birth control for 28 days prior to prescribing lenalidomide. Men must agree to use a latex condom during sexual contact with FCBP even if they have had a successful vasectomy, and must agree not to donate semen during study drug therapy and for a period of time after therapy. 10. Able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject's privacy regulations). 11. Able to take aspirin daily as prophylactic anticoagulation therapy (subjects intolerant to aspirin may use warfarin or low-molecular-weight heparin). Exclusion Criteria: 1. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years. 2. Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10\^9/L). 3. Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary disease, and symptomatic heart failure. 4. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia. 5. Treatment with any investigational drug within 2 weeks or 3 half lives (whichever is longer) of the first dose of elotuzumab. 6. Use of corticosteroids, thalidomide, bortezomib, or cytotoxic chemotherapy within 2 weeks of the first dose of elotuzumab except for steroids with little or no systemic absorption (ie, topical or inhaled steroids). 7. Prior lenalidomide therapy. 8. Prior peripheral stem-cell transplant within 12 weeks of the first dose of elotuzumab. 9. Treatment with nitrosoureas, such as carmustine (BiCNU), nitrogen mustard agents, or melphalan, within 6 weeks of first dose of elotuzumab. 10. Neuropathy ≥ Grade 3 or painful neuropathy ≥ Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v3.0). 11. Known active infections requiring IV antibiotic, antiviral, or antifungal therapy. 12. Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone. 13. Female subjects who are pregnant or breastfeeding. 14. Subjects with serum calcium (corrected for albumin) ≥ 12 mg/dL.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
    intervention Names
    1. Biological: elotuzumab
    2. Drug: lenalidomide
    3. Drug: dexamethasone oral
    4. Drug: dexamethasone injection
    label
    Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    type
    EXPERIMENTAL
  2. description
    Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
    intervention Names
    1. Biological: elotuzumab
    2. Drug: lenalidomide
    3. Drug: dexamethasone oral
    4. Drug: dexamethasone injection
    label
    Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    type
    EXPERIMENTAL
  3. description
    Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
    intervention Names
    1. Biological: elotuzumab
    2. Drug: lenalidomide
    3. Drug: dexamethasone oral
    4. Drug: dexamethasone injection
    label
    Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    type
    EXPERIMENTAL
  4. description
    Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
    intervention Names
    1. Biological: elotuzumab
    2. Drug: lenalidomide
    3. Drug: dexamethasone oral
    4. Drug: dexamethasone injection
    label
    Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    type
    EXPERIMENTAL
  5. description
    Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
    intervention Names
    1. Biological: elotuzumab
    2. Drug: lenalidomide
    3. Drug: dexamethasone oral
    4. Drug: dexamethasone injection
    label
    Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    2. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    3. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    4. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    5. Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    description
    Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
    name
    elotuzumab
    other Names
    1. HuLuc63
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    2. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    3. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    4. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    5. Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    description
    Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
    name
    lenalidomide
    type
    DRUG
  3. arm Group Labels
    1. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    2. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    3. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    4. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    5. Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    description
    Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
    name
    dexamethasone oral
    type
    DRUG
  4. arm Group Labels
    1. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    2. Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    3. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    4. Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)
    5. Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)
    description
    Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
    name
    dexamethasone injection
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
101
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    MTD was determined by testing increasing doses up to 20 mg/kg once daily dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (dose limiting toxicity \[DLT\]) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria for Adverse Events (CTCAE) Grade 4 neutropenia in specific conditions, platelets \< 10,000 cells/mm\^3 that do not recover to 25,000 cells/mm\^3; and specific non-hematologic/biochemical toxicities CTCAE Grade 3 or 4 (except fatigue and Grade 3 infections); CTCAE version 3.0 were used.
    measure
    Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Lenalidomide and Dexamethasone (Phase 1)
    time Frame
    4 weeks
  2. description
    ORR: Percentage of participants with confirmed complete response (CR; negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow), partial response (PR; ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to ≤200 mg per 24 hour; if serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC\] levels is required in place of the M-protein criteria; if serum and urine M-protein are unmeasurable, and serum FLC is also unmeasurable, a ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%; and, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas), very good PR (VGPR; normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence), or stringent CR (sCR; CR plus VGPR).
    measure
    Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 2)
    time Frame
    From date of randomization until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
secondary Outcomes
  1. description
    ORR: Percentage of participants with confirmed complete response (CR; negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow), partial response (PR; ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to ≤200 mg per 24 hour; if serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC\] levels is required in place of the M-protein criteria; if serum and urine M-protein are unmeasurable, and serum FLC is also unmeasurable, a ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%; and, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas), very good PR (VGPR; normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence), or stringent CR (sCR; CR plus VGPR).
    measure
    Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 1)
    time Frame
    From first dose of elotuzumab until 60 days following the last infusion (or before initiation of new therapy), up to 100.5 months
  2. description
    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either definitely related, probably related, possibly related or unrelated. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
    measure
    Number of Participants With Treatment-emergent Adverse Events (TEAEs)
    time Frame
    Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 60 days after the last dose of study drug (up to 95 months)
  3. description
    During Phase 1, a list of 118 pre-defined MedDRA preferred terms that had been adjudicated to be clinically relevant to infusion reactions by a safety committee was used to search for TEAEs that could potentially be associated with an infusion reaction following elotuzumab administration. Examples of these terms included angioedema, bronchospasm, chills, flushing, pyrexia, rash and urticaria. During Phase 2, the method for capturing TEAEs associated with an infusion reaction was modified to include investigators' designation of AEs judged as clinically relevant infusion reactions. The number of participants infusion reactions are provided overall and by highest toxicity grade (CTCAE v 3.0).
    measure
    Number of Participants With Infusion Reactions
    time Frame
    Cycles 1 and 2: Days 1, 8, 15, and 22 (day of infusion of elotuzumab) and Days 2, 9, 16, and 23 (day following infusion); and Cycles 3 and greater: Days 1 and 15 (day of infusion) and Days 2 and 16 (day after infusion) (up to 95 months)
  4. description
    Blood samples were collected during Phase 1, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours) and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). Blood samples were collected during Phase 2, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) and 2 hours post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). The samples were analyzed for the concentration of elotuzumab using validated analytical methods. Mean serum concentrations on Cycle 1, Days 1, 8, 15, and 22 (measured in μg/mL) are reported overall (across Phase 1 and Phase 2) by dose.
    measure
    Mean Serum Concentrations of Elotuzumab During Cycle 1
    time Frame
    Cycle 1: Days 1 (pre-infusion and 0.5, 2 and 4 hours post-infusion), 8 (pre-infusion and 0.5 and 2 hours post-infusion), 15 (pre-infusion and 0.5 hours and 2 hours post-infusion), and 22 (pre-infusion and 0.5, 2, and 4 hours post-infusion)
  5. description
    The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval. The Cmax of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.
    measure
    Maximum Serum Concentration (Cmax) of Elotuzumab
    time Frame
    Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1
  6. description
    The area under the plasma concentration-time curve (AUC; measured in ng\*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC24 of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.
    measure
    Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of Elotuzumab
    time Frame
    Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1
  7. description
    Systemic clearance (CL, measured in mL/kg/hr) is a measure of the efficiency with which a drug is irreversibly removed from the body. The CL of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.
    measure
    Systemic Clearance (CL) of Elotuzumab
    time Frame
    Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1
  8. description
    Volume of distribution (V, measured in L/kg) is the hypothetical volume of body fluid that would be required to dissolve the amount of drug needed to achieve the same concentration in the blood. The V of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.
    measure
    Volume of Distribution (V) of Elotuzumab
    time Frame
    Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1
  9. description
    The serum half-life of a drug (t1/2, measured in hours) is the time necessary to reduce the plasma concentration by half. The t1/2 of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.
    measure
    Serum Half-life (t1/2) of Elotuzumab
    time Frame
    Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1
  10. description
    Duration of response is defined as the time from the initial objective response to disease progression or death, whichever occurs first. The distribution of duration of response was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the duration of response distribution are provided.
    measure
    Duration of Response
    time Frame
    From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
  11. description
    TTP is defined as the time from first dose (phase 1) or time from randomization (phase 2) to disease progression. The distribution of TTP was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the TTP distribution are provided.
    measure
    Time to Progression (TTP)
    time Frame
    From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
  12. description
    PFS is defined as the time from first dose (phase 1) or time from randomization (phase 2) to disease progression or death. The distribution of PFS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the PFS distribution are provided.
    measure
    Progression-free Survival (PFS)
    time Frame
    From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
Full study description
brief Summary
The purpose of this study is to evaluate the combination of elotuzumab, lenalidomide, and dexamethasone in subjects with relapsed multiple myeloma.
Source references
references
  1. citation
    Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
    pmid
    26686406
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-99345515bb639fa5e4a4
      requested nct id
      NCT00742560
      primary nct id
      NCT00742560
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      9e5d6f76a98e10ac4fc9b6cf190a5b8c5b4694407f21b95b9ad532fef8c6d754
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-99345515bb639fa5e4a4
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00742560
      occurrences
      1. context exact
        NCT00742560
        end
        11
        exact text
        NCT00742560
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/341/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      201597b6043499c5d70f59a4240dde0b1fd2c580160cd0921d03829104c4f545

    Preserved source evidence · Not medical advice